A trial of a new medicine for cystic fibrosis and pancreatic problems
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This trial tests a new medicine (ANG003) for people with cystic fibrosis who have severe pancreatic problems. It looks at how safe and effective the medicine is, and whether it helps with digestion.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years or older (in the US) or 18 years or older (in the EU).
- You have been diagnosed with cystic fibrosis.
- You have severe pancreatic insufficiency, confirmed by a stool test showing low enzyme levels.
- You have been taking a stable dose of pancreatic enzyme replacement therapy (PERT) for at least 90 days before the study starts.
- Your body mass index (BMI) is at least 18.5 (if you are 18 or older) or at or above the 25th percentile for your age (if you are 12-17 years old).
- You do not have certain bowel or liver problems, and you have not had a lung or liver transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new pancreatic enzyme medicine (called NHS7108) for people with exocrine pancreatic insufficiency (EPI). EPI means your pancreas doesn't make enough enzymes to break down food properly. The study aims to see if this new medicine is safe and works well to help your body absorb nutrients.
This trial tests whether enzymes from microbes work as well as enzymes from pigs to help people with chronic pancreatitis digest food better. It aims to find a treatment that reduces symptoms like pain and poor digestion.
This study tests whether a special nutrition supplement can improve health in adults with cystic fibrosis and pancreatic insufficiency who are already on a modulator therapy. The goal is to see if the supplement helps with digestion and overall well-being.
This trial tests whether a pancreatic enzyme replacement therapy (PERT) can help people who still have digestive problems after a recent episode of acute pancreatitis. The goal is to see if it improves symptoms like stomach pain, bloating, or diarrhea.
This study tests how the body’s “incretin” hormones affect insulin (sugar control) in adults with cystic fibrosis and certain blood sugar patterns. It may help explain what drives diabetes risk in cystic fibrosis and how the body responds to these hormone signals.
This study looks at how often people with active Crohn’s disease also have trouble digesting food because the pancreas may not release enough enzymes (exocrine pancreatic insufficiency). It may help doctors better recognize this hidden problem in people whose Crohn’s is currently active.
Hear when a new Exocrine Pancreatic Insufficiency (EPI) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.